SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

February 25, 2019

Date of Report

 

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-37939 45-4497941
(State or other jurisdiction of
incorporation) 		(Commission File Number) (IRS Employer
Identification No.)

 

3200 Southwest Freeway

Suite 2240

Houston, Texas

  77027
(Address of principal executive offices)   (Zip Code)

 

(713) 400-6400

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On February 25, 2019, Marker Therapeutics, Inc. (“Marker” or the “Company”) issued a press release announcing a clinical update from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies. The data was reviewed in oral and poster presentations at the Transplantation & Cellular Therapy (“TCT”) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research (“ASBMT” and “CIBMTR”) The meetings took place in Houston, Texas from February 20-24, 2019.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

As previously announced by the Company on January 15, 2019, the Center for Cell and Gene Therapy at Baylor College of Medicine presented data from four abstracts at ASBMT and CIBMTR meetings between February 20-February 23, 2019. The presentations include: (i) an oral presentation regarding Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells; (ii) an oral presentation regarding Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse; (iii) an oral presentation regarding Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens; and (iv) a poster presentation regarding Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma. The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker Therapeutics, Inc. Copies of the presentation and posters are attached hereto as Exhibits 99.2, 99.3, 99.4, and 99.5, respectively. The presentations are available on Marker Therapeutics website at www.markertherapeutics.com under the caption “Recognition.”

 

The information furnished pursuant to Item 8.01 on this Form 8-K, including Exhibit 99.2, 99.3 and 99.4 and 99.5 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description  
   
99.1 Press release issued on February 25, 2019.
   
99.2 2019 TCT Meeting Presentation- Targeting Lymphomas Using Non-Engineered, Multi-Antigen-Specific T Cells.*
   
99.3 2019 TCT Meeting Presentation- Administering Leukemia-Directed Donor Lymphocytes to Patients with AML or MDS to Prevent or Treat Post-Allogeneic HSCT Relapse. *
   
99.4 2019 TCT Meeting Presentation- Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens.*
   
99.5 2019 TCT Meeting Poster Presentation- Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma.*

 

*Furnished herewith.

 

 

  

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 25 th day of February, 2019.

 

 

  MARKER THERAPEUTICS, INC.  
  ( Registrant)  
       
  BY: /s/ Michael Loiacono  
    Michael Loiacono    
    Chief Accounting Officer  

 

 

 

 

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Marker Therapeutics Charts.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Marker Therapeutics Charts.